Sudo R, Camara M, Kieling S, Marques I, Mesquita Y, Piepenbrink B
Eur J Pediatr. 2023; 183(1):61-71.
PMID: 37870611
DOI: 10.1007/s00431-023-05275-8.
Cabellos C, Guillem L, Pelegrin I, Tubau F, Ardanuy C, Gudiol F
Antimicrob Agents Chemother. 2022; 66(12):e0082022.
PMID: 36326246
PMC: 9764967.
DOI: 10.1128/aac.00820-22.
Erdem H, Oncul O
Curr Ther Res Clin Exp. 2014; 68(1):49-66.
PMID: 24678118
PMC: 3965998.
DOI: 10.1016/j.curtheres.2007.03.001.
Chung J, Kim B, Kwak Y, Kim T, Lee E, Choo E
Eur J Clin Microbiol Infect Dis. 2012; 31(11):3029-34.
PMID: 22661125
DOI: 10.1007/s10096-012-1657-z.
Loo V, Lavallee J, McAlear D, Robson H
Can J Infect Dis. 2012; 6(2):83-7.
PMID: 22416208
PMC: 3298062.
DOI: 10.1155/1995/725654.
Acute bacterial meningitis in infants and children: epidemiology and management.
Agrawal S, Nadel S
Paediatr Drugs. 2011; 13(6):385-400.
PMID: 21999651
DOI: 10.2165/11593340-000000000-00000.
Increasing chloramphenicol resistance in Streptococcus pneumoniae isolates from Papua New Guinean children with acute bacterial meningitis.
Manning L, Laman M, Greenhill A, Michael A, Siba P, Mueller I
Antimicrob Agents Chemother. 2011; 55(9):4454-6.
PMID: 21709079
PMC: 3165345.
DOI: 10.1128/AAC.00526-11.
Treatment of Drug-resistant Pneumococcal Meningitis.
Hameed N, Tunkel A
Curr Infect Dis Rep. 2011; 12(4):274-81.
PMID: 21308542
DOI: 10.1007/s11908-010-0110-7.
Therapy of suspected bacterial meningitis in Canadian children six weeks of age and older.
Paediatr Child Health. 2010; 6(3):147-60.
PMID: 20084227
PMC: 2804530.
DOI: 10.1093/pch/6.3.147.
Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis.
Force E, Taberner F, Cabellos C, Ribes S, Domenech A, Tubau F
Eur J Clin Microbiol Infect Dis. 2009; 28(7):807-11.
PMID: 19221815
DOI: 10.1007/s10096-009-0711-y.
Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis.
Force E, Taberner F, Cabellos C, Ribes S, Domenech A, Tubau F
Eur J Clin Microbiol Infect Dis. 2008; 27(8):685-90.
PMID: 18386085
DOI: 10.1007/s10096-008-0492-8.
Gram-positive cocci infections in intensive care: guide to antibacterial selection.
Alvarez-Lerma F, Grau S, Gracia-Arnillas M
Drugs. 2006; 66(6):751-68.
PMID: 16706550
DOI: 10.2165/00003495-200666060-00003.
Bacterial meningitis in children: critical review of current concepts.
Yogev R, Guzman-Cottrill J
Drugs. 2005; 65(8):1097-112.
PMID: 15907145
DOI: 10.2165/00003495-200565080-00005.
Therapeutic efficacy of meropenem for treatment of experimental penicillin-resistant pneumococcal meningitis.
Kim S, Jin J, Kang S, Jung S, Kim Y, Kim C
J Korean Med Sci. 2004; 19(1):21-6.
PMID: 14966336
PMC: 2822258.
DOI: 10.3346/jkms.2004.19.1.21.
Diagnosis and treatment of bacterial meningitis.
El Bashir H, Laundy M, Booy R
Arch Dis Child. 2003; 88(7):615-20.
PMID: 12818910
PMC: 1763168.
DOI: 10.1136/adc.88.7.615.
Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis.
Cottagnoud P, Pfister M, Cottagnoud M, Acosta F, Tauber M
Antimicrob Agents Chemother. 2003; 47(6):1943-7.
PMID: 12760871
PMC: 155819.
DOI: 10.1128/AAC.47.6.1943-1947.2003.
Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.
Cabellos C, Fernandez A, Maiques J, Tubau F, Ardanuy C, Viladrich P
Antimicrob Agents Chemother. 2003; 47(6):1907-11.
PMID: 12760866
PMC: 155831.
DOI: 10.1128/AAC.47.6.1907-1911.2003.
Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci.
Rodriguez-Cerrato V, McCoig C, Saavedra J, Barton T, Michelow I, Hardy R
Antimicrob Agents Chemother. 2002; 47(1):211-5.
PMID: 12499193
PMC: 148949.
DOI: 10.1128/AAC.47.1.211-215.2003.
Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.
Lamb H, Ormrod D, Scott L, Figgitt D
Drugs. 2002; 62(7):1041-89.
PMID: 11985490
DOI: 10.2165/00003495-200262070-00005.
Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis.
Cottagnoud P, Acosta F, Cottagnoud M, Tauber M
Antimicrob Agents Chemother. 2002; 46(5):1607-9.
PMID: 11959614
PMC: 127126.
DOI: 10.1128/AAC.46.5.1607-1609.2002.